PI3K/Akt/mTOR Compound Library

PI3K/Akt/mTOR Compound Library
SKU
MEXHY-L015-30
Packaging Unit
30 μl
Manufacturer
MedChemExpress

Availability: loading...
Price is loading...
Description: The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.
The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.
MCE owns a unique collection of 568 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.
MCE PI3K/Akt/mTOR Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 550 compounds supplied in 10 mM solution, 17 compounds supplied in 2 mM solution and 1 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

Advantages:
  • A unique collection of 568 small molecule inhibitors used for PI3K/Akt/mTOR pathway research.
  • Targets such as Akt, AMPK, DNA-PK, PDK-1, mTOR, PI3K, PTEN, etc.
  • A valuable tool for studying PI3K/Akt/mTOR-related survival, proliferation, and apoptosis of cells and related diseases.
  • Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by the FDA.
  • Structurally diverse, medicinally active, and cell permeable.
  • Rich documentation with structure, IC50, and summary.
  • NMR and HPLC validated to ensure high purity.
  • All compounds are in stock and continuously updated.


Formulation: A collection of 568 PI3K/Akt/mTOR pathway related compounds supplied as pre-dissolved Solutions or SolidSolution:550 compounds supplied in 10 mM solution,17 compounds supplied in 2 mM solution,1 compounds supplied in 3 mg/mL solution.

Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.

Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
More Information
SKU MEXHY-L015-30
Manufacturer MedChemExpress
Manufacturer SKU HY-L015-30
Green Labware No
Package Unit 30 μl
Quantity Unit STK
Product information (PDF)
×
MSDS (PDF)
×